In a move towards general cancer treatment, the FDA has approved Merck’s cancer drug for the treatment of any advanced tumor with microsatellite instability or DNA mismatch repair defects. Variants of these DNA indicators are present in genetically-linked cancers. The drug, Keytruda, was previously approved to treat some forms of lung cancer, melanoma, head & neck cancer, and Hodgkin’s lymphoma.  The recent approval for all types of cancers, however, shows progress in oncology treatment abilities. Read the full press release here.